AbCellera Appoints Dr. Stephen Quake to its Board of Directors [Yahoo! Finance]
BridgeBio Pharma, Inc. (BBIO)
Last bridgebio pharma, inc. earnings: 3/2 08:29 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Dr. Quake is a distinguished scientist, inventor, and entrepreneur who has made foundational contributions across diverse fields, including single molecule biophysics, microfluidics, single cell analysis, genomics, molecular diagnostics, and non-invasive prenatal testing. His work is represented in over 300 publications (h-index of 181) and 80+ patents and patent applications. "We are pleased to welcome Dr. Quake to AbCellera's Board of Directors. His presence reinforces our commitment to excellence in science and technology," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "He brings a distinctive combination of scientific breadth, creativity, and interdisciplinarity that resonates with AbCellera's culture and strategy." Dr. Quake is currently the Lee Otterson Professor of Bioengineering and Professor of Applied Physics at Stanford University and was previously the Thomas and Doris Everhart Professor of Applied Physics and Physics at Caltech. He has been elected to four U
Show less
Read more
Impact Snapshot
Event Time:
BBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBIO alerts
High impacting BridgeBio Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
BBIO
News
- BridgeBio to Participate in December Investor ConferencesGlobeNewswire
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Wells Fargo & Company from $76.00 to $84.00. They now have an "overweight" rating on the stock.MarketBeat
- BridgeBio Pharma, Inc. (BBIO) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]Seeking Alpha
- Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations [Yahoo! Finance]Yahoo! Finance
BBIO
Earnings
- 10/29/25 - Miss
BBIO
Sec Filings
- 11/24/25 - Form 4
- 11/20/25 - Form 144
- 11/19/25 - Form 4
- BBIO's page on the SEC website